The Board of Directors of Tianda Pharmaceuticals Limited informed the shareholders of the company and potential investors, based on preliminary assessment of the group's latest unaudited consolidated management accounts and the information currently available, the group is expected to record consolidated loss for the six months ending 30 September 2014, while consolidated profit was recorded in the corresponding period last year. Due to the suspension of original production line of Meng Sheng Pharmaceutical, its sales and earnings recorded a decline compared with the corresponding period last year. Therefore it is anticipated that the group's consolidated results for the six months ending 30 September 2014 will turn to a loss.